Fatty Liver and MASLD

Fatty Liver and MASLD Certificate Program

The Fatty Liver and MASLD certificate program delivers a comprehensive, clinically grounded curriculum designed for healthcare professionals, primary care physicians, gastroenterologists, hepatologists, dietitians, and advanced practice providers seeking to master the diagnosis and management of metabolic dysfunction-associated steatotic liver disease. This course transforms current evidence into practical skills, enabling you to confidently identify at-risk patients, interpret diagnostic findings, and implement personalized lifestyle and pharmacological strategies that slow disease progression and improve patient outcomes. By the end of the program, you will be equipped to lead MASLD care in your practice, from initial screening to long-term follow-up.

The program is structured as a beginner-friendly yet rigorous progression, moving from foundational liver physiology and fat metabolism through the latest terminology, epidemiological trends, and pathophysiological mechanisms, then into hands-on clinical tools such as imaging interpretation, biomarker analysis, and staging systems. It builds five core skill areas: risk stratification, diagnostic accuracy, therapeutic planning, comorbidity management, and patient education—each reinforced with real-world case scenarios and evidence-based guidelines. With MASLD now affecting over 30% of the global population and new pharmacotherapies emerging rapidly, this training is essential for clinicians who want to stay ahead of the curve and deliver modern, integrated care that addresses both hepatic and metabolic health.

What is Fatty Liver and MASLD?

Fatty liver disease, now formally termed metabolic dysfunction-associated steatotic liver disease (MASLD), is a spectrum of conditions characterized by excessive fat accumulation in hepatocytes, occurring in the absence of significant alcohol consumption and in the presence of at least one cardiometabolic risk factor. The subject encompasses the entire disease continuum—from simple hepatic steatosis, which is often asymptomatic, to metabolic dysfunction-associated steatohepatitis (MASH) with inflammation and hepatocyte injury, and ultimately to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Core concepts include the role of insulin resistance, lipotoxicity, oxidative stress, and gut-liver axis dysregulation in driving disease progression, as well as the nuanced criteria for diagnosis that distinguish MASLD from other liver diseases.

Today, MASLD has become the most common chronic liver condition worldwide, paralleling the global epidemics of obesity, type 2 diabetes, and metabolic syndrome. Its relevance extends far beyond hepatology, impacting cardiology, endocrinology, primary care, and public health, as MASLD is now recognized as an independent risk factor for cardiovascular disease, chronic kidney disease, and all-cause mortality. Recent shifts include the 2023 consensus redefinition from NAFLD to MASLD, which better captures metabolic drivers, and the approval of the first targeted pharmacologic agents, such as resmetirom, alongside a growing pipeline of therapies. In clinical practice, MASLD management is increasingly integrated into metabolic care pathways, with non-invasive fibrosis scores and elastography replacing routine biopsies, making early detection and intervention more feasible than ever before.

Mastering the subject of MASLD builds a robust skill stack that bridges metabolic medicine and hepatology, including proficiency in interpreting liver function tests, calculating fibrosis risk scores, counseling on evidence-based dietary patterns and exercise regimens, and selecting appropriate pharmacotherapy based on disease stage and comorbidities. This knowledge is invaluable for professionals in hospital settings, outpatient clinics, research institutions, and pharmaceutical development, as well as for public health policymakers designing screening programs. For individual learners, understanding MASLD empowers them to improve patient quality of life, reduce long-term complications, and contribute to a field that is rapidly evolving—making this subject not only clinically essential but also intellectually rewarding for those committed to advancing metabolic and liver health.